Keerthana,Lavakumar, Vishwambar A prospective observational study on distribution pattern of adverse effects of bronchodilators among bronchial asthma and COPD patients in a tertiary care teaching hospital in a rural area of Kancheepuram district
Background: Bronchodilators are the most commonly used drugs for Bronchial Asthma and COPD. Adverse Drug Reactions(ADR) of the Bronchodilators have been reported. Objectives:
(i)To study the distribution pattern of adverse effects of bronchodilators at initiation or during the course of therapy (ii) To make a causality assessment of adverse effect identified using WHO ADR probability scale. (iii) To identify next drug tolerated better by him/her. Materials and Methods: An observational study lasted for duration of two months .Inclusion Criteria: All patients reporting ADR after initiation of bronchodilator or during the course of bronchodilator therapy for Bronchial Asthma/ COPD within the study period were included. The suspected adverse effect was noted and documented. Causality assessment based on WHO scale was employed. Results: During the study period, 10 patients reported to have ADR for bronchodilators were identified and WHO Causality Scale for ADR was applied and the better drug tolerated by the patient could be noted. Conclusion: Inhalational formulations were better tolerated by the patients. Longer acting preparations were also better for the patients
bronchodilators, shri sathya sai medical college, adverse drug reactions
2. WHO-ADR http.//www.who.int.//,https//www.researchgate.net publications.
3. Boosley CM, Parry DT, Cochrane GM .Patient compliance with inhaled medication doses combining with beta agonists with corticosteroids improve compliance.
4. Jonne JW, Ridley DF, Mracucci, Druzws Rook JC ,Objective and subjective tremor responses to oral beta-2 agonists on first exposure.
5. Brewis RAL. Patient education self management plans and peak flow measurements. Respir.Med.1991:85;45
6. Brown JP, Greville WH, Finucane KE, Asthma and irreversible airflow obstruction.
7. British Thoracic Society. The British guide-Times on asthma management .1995 reviews and position management thorax 1997.
8. Morley J. Beta agonists and asthma mortality: deja vu. Clin Exp Allergy. 1992:22:724-5.
9. Gonnelli S,Caffarelli C,Maggi S ,etal Effect of inhaled glucocorticoids on vertebral fractures and yeast infections in COPD and asthma patients .The EOLO study Calcif tissue int.2010:87:137-43.
10. Casale TB,Nalson HS,sticker WE, Raff H.Newman KB .Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients .Am allergy asthma Immunol.2001:87:379-85.
11. Rohatagi S.Luo,Y.shenL,etaL protein hinding and its potential for eliciting minimal systemic side effects with novel inhaled corticostereoids ,budesonide.AMJ Ther.2005:12;201-9
12. Voss H-P, Donnell D, Bast A. Atypical molecular pharmacology of a new long-acting b2-adrenoceptor agonist, TA-2005. Eur J Pharmacol 1992; 227: 403–409
13. Cazzola M, Matera MG, Lo¨ tvall J. Ultra long-acting b2-agonistsin development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005; 14: 775–783
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.